Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis

Liu, Chen–Hua; Peng, Cheng Yuan; Fang, Yu‐Jen; Kao, Wei‐Yu; Yang, Sheng‐Shun; Lin, Cheng‐Kuan; Lai, Hsueh‐Chou; Su, Wen‐Pang; Fang, Sheng-Uei; Chang, Chi-Jen; Su, Tung‐Hung; Liu, Chun‐Jen; Chen, Pei‐Jer; Chen, Ding‐Shinn

doi:10.1038/s41598-020-66182-8

Cited by 9 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Across 3817 patients, only 35 were on peritoneal dialysis. 9 , 22 , 23 , 24 , 26 , 29 , 30 , 31 , 34 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 The s...…”

Section: Ckd G4–g5ndunclassified

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

Section: Ckd G4–g5ndunclassified

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

“…Telcagepant is in a clinical phase 3 trial for acute migraine [ 89 ], but it is not yet under the clinical phase for COVID-19. Elbasvir is an FDA-approved drug for the treatment of hepatitis C virus genotype 1b (HCV GT1b) patients [ 90 ], and it is supported for COVID-19 by other studies [ 91 ], but is not yet considered for a clinical trial for COVID-19. To compare our suggested eight drug molecules against the two FDA-approved drugs (Molnupiravir and Nirmatrelvir) for COVID-19, we investigated their docking scores (kcal/mol) with our proposed and top-ranked published target proteins and found that our proposed drug molecules produced higher binding affinity scores in both cases.…”

Section: Discussionmentioning

confidence: 99%

Discovery of Bacterial Key Genes from 16S rRNA-Seq Profiles That Are Associated with the Complications of SARS-CoV-2 Infections and Provide Therapeutic Indications

Kibria,

Ali,

Yaseen

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

SARS-CoV-2 infections, commonly referred to as COVID-19, remain a critical risk to both human life and global economies. Particularly, COVID-19 patients with weak immunity may suffer from different complications due to the bacterial co-infections/super-infections/secondary infections. Therefore, different variants of alternative antibacterial therapeutic agents are required to inhibit those infection-causing drug-resistant pathogenic bacteria. This study attempted to explore these bacterial pathogens and their inhibitors by using integrated statistical and bioinformatics approaches. By analyzing bacterial 16S rRNA sequence profiles, at first, we detected five bacterial genera and taxa (Bacteroides, Parabacteroides, Prevotella Clostridium, Atopobium, and Peptostreptococcus) based on differentially abundant bacteria between SARS-CoV-2 infection and control samples that are significantly enriched in 23 metabolic pathways. A total of 183 bacterial genes were found in the enriched pathways. Then, the top-ranked 10 bacterial genes (accB, ftsB, glyQ, hldD, lpxC, lptD, mlaA, ppsA, ppc, and tamB) were selected as the pathogenic bacterial key genes (bKGs) by their protein–protein interaction (PPI) network analysis. Then, we detected bKG-guided top-ranked eight drug molecules (Bemcentinib, Ledipasvir, Velpatasvir, Tirilazad, Acetyldigitoxin, Entreatinib, Digitoxin, and Elbasvir) by molecular docking. Finally, the binding stability of the top-ranked three drug molecules (Bemcentinib, Ledipasvir, and Velpatasvir) against three receptors (hldD, mlaA, and lptD) was investigated by computing their binding free energies with molecular dynamic (MD) simulation-based MM-PBSA techniques, respectively, and was found to be stable. Therefore, the findings of this study could be useful resources for developing a proper treatment plan against bacterial co-/super-/secondary-infection in SARS-CoV-2 infections.

show abstract

“…One major limitation of the information reported above is that it is mostly based on industry-funded studies, and these kinds of studies are more likely to be published if results are favourable [30]. However, numerous real-life studies on the same point have been completed supporting the conclusions reported above [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45].…”

Section: Pi-containing Sof-free Daas (Real World Studies)mentioning

confidence: 99%

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease

Fabrizi

Cerutti

2021

Pathogens

View full text Add to dashboard Cite

Background: Hepatitis C virus infection remains common in patients with chronic kidney disease, including those on maintenance dialysis. The relationship between hepatitis C virus infection and chronic kidney disease is bi-directional; in fact, HCV is both a cause and consequence of chronic kidney disease. According to a systematic review with meta-analysis of observational studies (n = 23 studies) (n = 574,081 patients on long-term dialysis), anti-HCV positive serologic status was an independent and significant risk factor for death in patients with advanced chronic kidney disease on long-term dialysis. The overall estimate for adjusted mortality (all-cause death risk) with HCV was 1.26 (95% CI, 1.18; 1.34) (p < 0.0001). Interferon-based therapies are biased by low efficacy/safety in chronic kidney disease, but the advent of direct-acting antiviral drugs has made a paradigm shift in the treatment of HCV-infection. These medications give interruption of viral replication because they target specific non-structural viral proteins; four classes of DAAs exist-NS3/4A protease inhibitors, NS5A inhibitors, NS5B nucleoside and non-nucleoside polymerase inhibitors. All-oral, interferon-free, ribavirin-free combinations of DAAs are now available. Aim: The goal of this narrative review is to report the available treatment options for HCV in advanced chronic kidney disease. Methods: We have made an extensive review of the medical literature and various research engines have been adopted. Results: Some combinations of DAAs are currently recommended for HCV in advanced CKD (including patients on maintenance dialysis): elbasvir/grazoprevir; glecaprevir/pibrentasvir; and sofosbuvir-based regimens. Solid evidence, based on registration and “real life” studies supports their efficacy (SVR rates > 90%) and safety even in patients with advanced CKD. No dosage adjustment is necessary and treatment duration is 8–12 weeks. However, recent data highlight that many patients with advanced CKD remain untreated, and numerous barriers to antiviral treatment of HCV still exist. Whether successful antiviral therapy with DAAs will translate into improved survival in the advanced CKD population is another point of future research.

show abstract

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis

Abstract: In conclusion, our multicenter prospective study confirms that EBR/GZR for 12 weeks is effective for East-Asian HCV GT1b patients receiving hemodialysis. Furthermore, the tolerability is also excellent for these patients receiving EBR/GZR.

Cited by 9 publications

References 27 publications

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Discovery of Bacterial Key Genes from 16S rRNA-Seq Profiles That Are Associated with the Complications of SARS-CoV-2 Infections and Provide Therapeutic Indications

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease

Contact Info

Product

Resources

About